NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Up 26.3% in April

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNGet Rating) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totalling 60,000 shares, an increase of 26.3% from the April 15th total of 47,500 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average daily volume of 4,180,000 shares, the short-interest ratio is currently 0.0 days.

A number of institutional investors have recently added to or reduced their stakes in NRSN. Citadel Advisors LLC acquired a new stake in NeuroSense Therapeutics in the fourth quarter worth about $135,000. Bank of Montreal Can purchased a new position in shares of NeuroSense Therapeutics in the 1st quarter valued at approximately $65,000. Finally, Jane Street Group LLC acquired a new stake in NeuroSense Therapeutics in the 1st quarter worth approximately $173,000. Institutional investors own 43.83% of the company’s stock.

NRSN stock traded up $0.01 on Wednesday, hitting $1.28. 102,928 shares of the company’s stock were exchanged, compared to its average volume of 2,944,034. NeuroSense Therapeutics has a 12-month low of $1.23 and a 12-month high of $8.18. The stock’s 50 day simple moving average is $2.49.

About NeuroSense Therapeutics (Get Rating)

NeuroSense Therapeutics Ltd. is a clinical-stage biopharmaceutical company focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease and CogniC for the treatment of Alzheimer's disease.

Featured Articles

Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with's FREE daily email newsletter.